Analysts Offer Predictions for MOLN Q1 Earnings

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Molecular Partners in a report issued on Tuesday, January 27th. HC Wainwright analyst R. Burns anticipates that the company will post earnings of ($0.41) per share for the quarter. HC Wainwright currently has a “Strong-Buy” rating on the stock. The consensus estimate for Molecular Partners’ current full-year earnings is ($1.93) per share. HC Wainwright also issued estimates for Molecular Partners’ Q2 2026 earnings at ($0.43) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.44) EPS, FY2026 earnings at ($1.70) EPS, Q1 2027 earnings at ($0.45) EPS, Q2 2027 earnings at ($0.41) EPS, Q3 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.39) EPS and FY2027 earnings at ($1.64) EPS.

Molecular Partners (NASDAQ:MOLN) last announced its quarterly earnings data on Thursday, October 30th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.05.

MOLN has been the subject of a number of other reports. JPMorgan Chase & Co. cut their price objective on Molecular Partners from $4.00 to $3.75 and set a “neutral” rating for the company in a research report on Monday, December 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Molecular Partners in a report on Monday, December 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $9.58.

Molecular Partners Stock Performance

NASDAQ MOLN opened at $4.00 on Wednesday. The firm has a market capitalization of $161.52 million, a P/E ratio of -2.08 and a beta of 1.07. The firm’s fifty day moving average price is $4.24 and its two-hundred day moving average price is $3.94. Molecular Partners has a 1 year low of $3.36 and a 1 year high of $5.35.

Molecular Partners News Summary

Here are the key news stories impacting Molecular Partners this week:

• Positive Sentiment: HC Wainwright reiterated a “Strong?Buy” and issued detailed EPS forecasts that are less negative than Street consensus (HCW: FY2026 (?$1.70), FY2027 (?$1.64) vs consensus (?$1.93)). The note includes quarterly EPS lines (e.g., Q1?Q4 2026: about ?$0.41 to ?$0.44; 2027 quarters ~?$0.45 to ?$0.39), implying a modest improvement in losses that can support investor optimism. HC Wainwright Research Note (MarketBeat)
• Neutral Sentiment: These are analyst projections, not company guidance or reported results — they signal improved expectations but carry the normal execution and clinical development risks for a biopharma. Investors should watch upcoming company updates, clinical readouts, and cash?runway disclosures as the next catalysts.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.